Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
AssigneesBiogen, Inc., University of California
InventorsJeffrey Browning, Carl F. Ware
Life of this patent
Estimating the term…
Loading patent…
AssigneesBiogen, Inc., University of California
InventorsJeffrey Browning, Carl F. Ware
Estimating the term…
This invention relates to lymphotoxin-β, a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23.D7 cells. This invention also relates to complexes formed between lymphotoxin-β and other peptides such as lymphotoxin-α and to complexes comprising multiple subunits of lymphotoxin-β. These proteins and complexes are useful in holding LT-α formed within the cell on the cell surface where the LT-α/LT-β complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-α/LT-β complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT-β.
A method for treating or lessening the advancement, severity, or effects of neoplasia, comprising administering an effective amount of a composition comprising a pharmaceutically acceptable carrier and a polypeptide complex comprising a first polypeptide selected from a group consisting of
Dependencies are inferred from the claim text.